SOURCE: Vicor Technologies, Inc.

October 30, 2006 11:42 ET

Vicor Technologies to Present at the Rodman & Renshaw Eighth Annual Healthcare Conference 2006

Company Anticipates U.S. 510(k) Approval in 2008, European Commercialization Late 2007, for Its PD2i Cardiac Analyzer for Risk Stratification

BOCA RATON, FL -- (MARKET WIRE) -- October 30, 2006 -- Vicor Technologies, Inc., developer of the Vicor PD2i Cardiac Analyzer, a patented risk stratification device for Sudden Cardiac Death (SCD), today announced that David H. Fater, President and Chief Executive Officer, will present an overview of the Company, including Vicor's proprietary device, the initiation of a key 510(k) trial and commercialization strategy, at the Rodman & Renshaw Eighth Annual Healthcare Conference. Vicor Technologies will present at the Conference on Wednesday, November 8, 2006, at 2:30 p.m. (EST). A live webcast of this presentation will be available at

http://www.wsw.com/webcast/rrshq10/vicor/

and will continue to be available for replay for 90 days after the presentation.

In making the announcement, Mr. Fater said, "Vicor has just begun a pivotal clinical trial, the VITAL Trial, for our proprietary PD2i Cardiac Analyzer, being coordinated by the Harvard Clinical Research Institute, a Harvard University affiliate. Upon anticipated satisfactory results at the conclusion of the Trial, in approximately 18 months, we will seek 510(k) clearance for the PD2i Analyzer from the FDA in order to commence commercial sales in the United States."

Mr. Fater added, "We have also signed a merger agreement in order to complete a transition to publicly held status. The deal is detailed in recent regulatory filings, and is expected to be completed by early 2007. We are also seeking a $5 million financing round which will enable us to move the PD2i Cardiac Device through the development process to U.S. market launch. We anticipate European sales before that in 2007."

The VITAL Trial is an acronym for "Prospective, Multi-Center Study of the Ability of the PD2i Cardiac Analyzer to Predict Risk of VentrIcular TachyArrhythmia Events such as, Sudden Cardiac Death VentricuLar Fibrillation (VF) or Ventricular Tachycardia (VT) in High Risk Patients".

To access Vicor Technologies presentation:

Wednesday November 8, 2006, 2:30 p.m. (EST).
A live webcast of this presentation will be available at
http://www.wsw.com/webcast/rrshq10/vicor/
and will continue to be available for replay for 90 days after the
presentation.
About Vicor Technologies, Inc.

Vicor Technologies' medical device, the PD2i Cardiac Analyzer, which is based on a patented, proprietary algorithm, accurately risk stratifies patients into those who are at high or low risk of suffering a fatal arrhythmic event or Sudden Cardiac Death (SCD) within a six month time frame. SCD is the leading cause of natural death in the United States each year with 500,000 reported cases.

Vicor's PD2i Cardiac Analyzer addresses a significant health care issue which involves a patient cohort of at least 12,000,000 patients. This patient cohort is composed of the MADIT-II (Multicenter Automatic Defibrillator Implantation Trial II)/SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) patient population; many of which may need an ICD (Implantable Cardioverter Defibrillator) as life saving therapy. However, it has been noted in recent registry studies that over 70% of implanted ICD's never have an appropriate firing. This over implantation has led to a substantial and unnecessary medical cost burden. Over-implantation of this patient cohort also puts them at risk because of the complications which can accompany this surgery.

Vicor's PD2i Cardiac Analyzer addresses the growing need for the medical community to be able to accurately risk stratify patients who are at high or low risk of suffering a fatal arrhythmic event. This will lead to a high quality of patient care, the minimization of medical expenses, and enhancing the patient's Quality of Life. Vicor Technologies has only one competitor, and is uniquely positioned to address this substantial unmet medical need. For more information visit the company web site www.vicortech.com.

About the Rodman & Renshaw Eighth Annual Healthcare Conference

The Rodman & Renshaw Eighth Annual Healthcare Conference will be held on November 6-8, 2006 at the New York Palace Hotel, New York, NY. The Conference will include presentations by over 300 companies, as well as experts from the medical, scientific and investment communities. The Conference will be attended by investors, venture capitalists, company executives, scientists and other industry leaders.

For more information about the Rodman & Renshaw Healthcare Conference in New York City, NY, please visit http://www.rodmanandrenshaw.com.

This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, anticipated, could, will, might, plan, projection, forecast, expect, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of the PD2i, the uncertainty of successful completion of any such trials, the fact that the Company has not succeeded in commercializing the PD2i Cardiac Device, and risk that the Device might not prove to be effective. A more extensive set of risks is set forth in Vicor Technologies SEC filings. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.

Contact Information

  • INVESTOR CONTACT:
    Robert Giordano ROI Associates
    212.495.0201
    Email Contact

    COMPANY CONTACT:
    David Fater
    President & CEO
    Vicor Technologies, Inc.
    800.998.9964
    www.vicortech.com